Ziconotide, an intrathecal analgesic for the management of chronic intractable pain, binds with high affinity to N-type calcium channels in neuronal tissue and obstructs neurotransmission. In three pivotal, well designed trials of 5-6 or 21 days' duration, titrated ziconotide was significantly more effective than placebo in treating chronic malignant or nonmalignant pain as assessed by mean percentage improvements from baseline in Visual Analogue Scale Pain Intensity scores. Improvements in secondary endpoints (e.g. proportion of patients who responded or achieved pain relief and the change in opioid use) generally support the efficacy of ziconotide over placebo. Ziconotide maintains its analgesic efficacy in preliminary results from long-term, open-label trials (data available for up to 12 months). Most ziconotide-related adverse events are neurological, mild to moderate in severity, resolve over time and reverse without sequelae on drug discontinuation. Low initial doses of ziconotide and gradual titration to onset of analgesia reduces the incidence and severity of adverse events. No evidence of respiratory depression has been reported with intrathecal ziconotide.
AuthorsKatherine A Lyseng-Williamson, Caroline Perry
JournalCNS drugs (CNS Drugs) Vol. 20 Issue 4 Pg. 331-8; discussion 339-41 ( 2006) ISSN: 1172-7047 [Print] New Zealand
PMID16599651 (Publication Type: Evaluation Studies, Journal Article)
Chemical References
  • Neuroprotective Agents
  • omega-Conotoxins
  • ziconotide
  • Animals
  • Clinical Trials as Topic
  • Humans
  • Neuroprotective Agents (pharmacology, therapeutic use)
  • Pain Measurement
  • Pain, Intractable (drug therapy)
  • omega-Conotoxins (pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: